Rapid corneal thinning and perforated ulcerative keratitis in a patient
... of severe PUK associated with relapsing polychondritis. Topical and oral steroids are often insufficient. In refractory and destructive PUK, high-dose pulse therapy with intravenous steroids and immunosuppressants is often necessary [6]. Before starting steroids, it is important to perform corneal s ...
... of severe PUK associated with relapsing polychondritis. Topical and oral steroids are often insufficient. In refractory and destructive PUK, high-dose pulse therapy with intravenous steroids and immunosuppressants is often necessary [6]. Before starting steroids, it is important to perform corneal s ...
CYANOKIT® Administration Guide
... Substantial increases in blood pressure may occur following CYANOKIT therapy. Elevations in blood pressure (≥180 mmHg systolic or ≥110 mmHg diastolic) were observed in approximately 18% of healthy subjects receiving hydroxocobalamin 5 g and 28% of subjects receiving 10 g. Usage may interfere with so ...
... Substantial increases in blood pressure may occur following CYANOKIT therapy. Elevations in blood pressure (≥180 mmHg systolic or ≥110 mmHg diastolic) were observed in approximately 18% of healthy subjects receiving hydroxocobalamin 5 g and 28% of subjects receiving 10 g. Usage may interfere with so ...
Ibuprofen and paracetamol for patent ductus arteriosus
... in premature infants during treatment for PDA [7]. Desfrere et al. demonstrated, in double blind randomized study in a cohort of infants of ≤ 29 weeks of gestational age, that the currently recommended dose regimen of ibuprofen (10-5-5 mg/kg/day) is associated with a low estimated probability (30.6% ...
... in premature infants during treatment for PDA [7]. Desfrere et al. demonstrated, in double blind randomized study in a cohort of infants of ≤ 29 weeks of gestational age, that the currently recommended dose regimen of ibuprofen (10-5-5 mg/kg/day) is associated with a low estimated probability (30.6% ...
plavix* data sheet
... Clopidogrel and the main circulating metabolite bind reversibly in vitro to human plasma proteins (98% and 94% respectively). The binding is non saturable in vitro over a wide concentration range. Following an oral dose of 14C-labelled clopidogrel in man, approximately 50% was excreted in the urine ...
... Clopidogrel and the main circulating metabolite bind reversibly in vitro to human plasma proteins (98% and 94% respectively). The binding is non saturable in vitro over a wide concentration range. Following an oral dose of 14C-labelled clopidogrel in man, approximately 50% was excreted in the urine ...
Amstan Tablets.FH11
... Amlodipine and Valsartan are antihypertensive compounds with complementary mechanisms to control blood pressure in patients with essential hypertension. The combination of these substances has an additive antihypertensive effect, reducing blood pressure to a greater degree than either component alon ...
... Amlodipine and Valsartan are antihypertensive compounds with complementary mechanisms to control blood pressure in patients with essential hypertension. The combination of these substances has an additive antihypertensive effect, reducing blood pressure to a greater degree than either component alon ...
PRODUCT INFORMATION MS Contin® modified release tablets 5
... pressure; head injury; brain tumour; paralytic ileus, delayed gastric emptying, suspected surgical and acute abdomen; severe liver disease, incipient hepatic encephalopathy; severe renal dysfunction; concomitant monoamine oxidase inhibitors (MAOIs), or within 14 days of such therapy (see INTERACTION ...
... pressure; head injury; brain tumour; paralytic ileus, delayed gastric emptying, suspected surgical and acute abdomen; severe liver disease, incipient hepatic encephalopathy; severe renal dysfunction; concomitant monoamine oxidase inhibitors (MAOIs), or within 14 days of such therapy (see INTERACTION ...
FENTANYL CITRATE INJECTION, USP
... significant decrease in the pregnancy rate of all experimental groups. This decrease was most pronounced in the high dosed group (1.25 mg/kg-12.5X human dose) in which one of twenty animals became pregnant. Pregnancy — Category C: Fentanyl citrate has been shown to impair fertility and to have an em ...
... significant decrease in the pregnancy rate of all experimental groups. This decrease was most pronounced in the high dosed group (1.25 mg/kg-12.5X human dose) in which one of twenty animals became pregnant. Pregnancy — Category C: Fentanyl citrate has been shown to impair fertility and to have an em ...
Review
... and it seems possible that the increase in MICs may be associated with the emergence of these strains. In the case of hGISA, glycopeptide therapy kills the dominant glycopeptide-susceptible population, allowing the glycopeptide-resistant subpopulation to predominate. hGISA infection is associated wi ...
... and it seems possible that the increase in MICs may be associated with the emergence of these strains. In the case of hGISA, glycopeptide therapy kills the dominant glycopeptide-susceptible population, allowing the glycopeptide-resistant subpopulation to predominate. hGISA infection is associated wi ...
SURVEILLANCE OF ANTIBIOTIC CONSUMPTION AND ANTIBIOTIC RESISTANCE IN SWEDISH INTENSIVE CARE UNITS
... were studied during two weeks in 2000. Paper 5 investigated Pseudomonas aeruginosa isolates in order to detect crosstransmission with genotype obtained by AFLP, and antibiogram-based cluster analysis was also performed in order to see if this could be a quicker and easier substitute for AFLP. ...
... were studied during two weeks in 2000. Paper 5 investigated Pseudomonas aeruginosa isolates in order to detect crosstransmission with genotype obtained by AFLP, and antibiogram-based cluster analysis was also performed in order to see if this could be a quicker and easier substitute for AFLP. ...
simvastatin tablets usp - Lupin Pharmaceuticals, Inc.
... with CHD and baseline total cholesterol 212-309 mg/dL (5.5-8.0 mmol/L). In this multicenter, randomized, doubleblind, placebo-controlled study, patients were treated with standard care, including diet, and either simvastatin 20-40 mg/day (n=2,221) or placebo (n=2,223) for a median duration of 5.4 ye ...
... with CHD and baseline total cholesterol 212-309 mg/dL (5.5-8.0 mmol/L). In this multicenter, randomized, doubleblind, placebo-controlled study, patients were treated with standard care, including diet, and either simvastatin 20-40 mg/day (n=2,221) or placebo (n=2,223) for a median duration of 5.4 ye ...
Full Prescribing Information
... TOPAMAX® can cause hyperchloremic, non-anion gap, metabolic acidosis (i.e., decreased serum bicarbonate below the normal reference range in the absence of chronic respiratory alkalosis). This metabolic acidosis is caused by renal bicarbonate loss due to carbonic anhydrase inhibition by TOPAMAX®. TOP ...
... TOPAMAX® can cause hyperchloremic, non-anion gap, metabolic acidosis (i.e., decreased serum bicarbonate below the normal reference range in the absence of chronic respiratory alkalosis). This metabolic acidosis is caused by renal bicarbonate loss due to carbonic anhydrase inhibition by TOPAMAX®. TOP ...
US Prescribing Information
... TOPAMAX® can cause hyperchloremic, non-anion gap, metabolic acidosis (i.e., decreased serum bicarbonate below the normal reference range in the absence of chronic respiratory alkalosis). This metabolic acidosis is caused by renal bicarbonate loss due to carbonic anhydrase inhibition by TOPAMAX®. TOP ...
... TOPAMAX® can cause hyperchloremic, non-anion gap, metabolic acidosis (i.e., decreased serum bicarbonate below the normal reference range in the absence of chronic respiratory alkalosis). This metabolic acidosis is caused by renal bicarbonate loss due to carbonic anhydrase inhibition by TOPAMAX®. TOP ...
Updated European Heart Rhythm Association - prof
... anticoagulants’ section). Also patient age, weight, renal function (see ‘Patients with chronic kidney disease’ section), and other comorbidities influence the choice, and are discussed in many of the sections below. In some patients, proton pump inhibitors (PPIs) may be considered to reduce the risk ...
... anticoagulants’ section). Also patient age, weight, renal function (see ‘Patients with chronic kidney disease’ section), and other comorbidities influence the choice, and are discussed in many of the sections below. In some patients, proton pump inhibitors (PPIs) may be considered to reduce the risk ...
PRODUCT INFORMATION ViruPOS OPHTHALMIC OINTMENT
... 3 sc doses of 100 mg/kg aciclovir on gestation day 10, fetal abnormalities, such as head and tail anomalies, were reported). The clinical relevance of these findings is uncertain. There have been no adequate and well controlled studies concerning the safety of aciclovir in pregnant women. Only small ...
... 3 sc doses of 100 mg/kg aciclovir on gestation day 10, fetal abnormalities, such as head and tail anomalies, were reported). The clinical relevance of these findings is uncertain. There have been no adequate and well controlled studies concerning the safety of aciclovir in pregnant women. Only small ...
product information
... At the endpoint the percentages of ITT patients with complete cure in the RejuveNail Antifungal group (5.7%) were higher than in the reference group (3.2%), compared with 0% for the placebo group. Similarly, the responder rate for RejuveNail (24%) was higher than the reference group (17.3%) and sign ...
... At the endpoint the percentages of ITT patients with complete cure in the RejuveNail Antifungal group (5.7%) were higher than in the reference group (3.2%), compared with 0% for the placebo group. Similarly, the responder rate for RejuveNail (24%) was higher than the reference group (17.3%) and sign ...
Updated European Heart Rhythm Association Practical
... anticoagulants’ section). Also patient age, weight, renal function (see ‘Patients with chronic kidney disease’ section), and other comorbidities influence the choice, and are discussed in many of the sections below. In some patients, proton pump inhibitors (PPIs) may be considered to reduce the risk ...
... anticoagulants’ section). Also patient age, weight, renal function (see ‘Patients with chronic kidney disease’ section), and other comorbidities influence the choice, and are discussed in many of the sections below. In some patients, proton pump inhibitors (PPIs) may be considered to reduce the risk ...
(Cannabis genus) for use as animal feed
... distortions) in patients undergoing cancer chemotherapy that had received oral doses of 15 mg THC/m2 (square meter of body surface) corresponding to 25 mg THC for an average adult (body surface: 1.7 m2). A reduction to 5 mg THC/m2, about 8-10 mg THC, produced only mild reactions. In a study by Fryt ...
... distortions) in patients undergoing cancer chemotherapy that had received oral doses of 15 mg THC/m2 (square meter of body surface) corresponding to 25 mg THC for an average adult (body surface: 1.7 m2). A reduction to 5 mg THC/m2, about 8-10 mg THC, produced only mild reactions. In a study by Fryt ...
Updated European Heart Rhythm Association
... anticoagulants’ section). Also patient age, weight, renal function (see ‘Patients with chronic kidney disease’ section), and other comorbidities influence the choice, and are discussed in many of the sections below. In some patients, proton pump inhibitors (PPIs) may be considered to reduce the risk ...
... anticoagulants’ section). Also patient age, weight, renal function (see ‘Patients with chronic kidney disease’ section), and other comorbidities influence the choice, and are discussed in many of the sections below. In some patients, proton pump inhibitors (PPIs) may be considered to reduce the risk ...
Updated European Heart Rhythm Association Practical Guide on the
... anticoagulants’ section). Also patient age, weight, renal function (see ‘Patients with chronic kidney disease’ section), and other comorbidities influence the choice, and are discussed in many of the sections below. In some patients, proton pump inhibitors (PPIs) may be considered to reduce the risk ...
... anticoagulants’ section). Also patient age, weight, renal function (see ‘Patients with chronic kidney disease’ section), and other comorbidities influence the choice, and are discussed in many of the sections below. In some patients, proton pump inhibitors (PPIs) may be considered to reduce the risk ...
Name: Paracetamol
... Certain packs of paracetamol are currently readily available for adults in the grocery channel; however there are no preparations of Paracetamol suitable for use in children available in the grocery channel. Liquid paracetamol for use in children has been available in New Zealand since its registrat ...
... Certain packs of paracetamol are currently readily available for adults in the grocery channel; however there are no preparations of Paracetamol suitable for use in children available in the grocery channel. Liquid paracetamol for use in children has been available in New Zealand since its registrat ...
Risperdal/Risperdal M-Tab/ Risperdal Consta (risperidone)
... At lower dosages, Risperdal is generally well tolerated. Common side effects include sedation, dizziness, headache, nausea, vomiting, constipation, insomnia, and agitation. There is a higher incidence of extrapyramidal symptoms (EPS) when the dosage of Risperdal exceeds 6 mg/day. EPS are neurologica ...
... At lower dosages, Risperdal is generally well tolerated. Common side effects include sedation, dizziness, headache, nausea, vomiting, constipation, insomnia, and agitation. There is a higher incidence of extrapyramidal symptoms (EPS) when the dosage of Risperdal exceeds 6 mg/day. EPS are neurologica ...
new zealand data sheet
... resultant decrease in systemic exposure to the antineoplastic might reduce it efficacy, and increased dosage would be needed in patients receiving this drugs to guarantee equivalent exposure. Antiprotozoals: Metronidazole – Plasma concentrations are increased by Phenobarbital, with a consequent redu ...
... resultant decrease in systemic exposure to the antineoplastic might reduce it efficacy, and increased dosage would be needed in patients receiving this drugs to guarantee equivalent exposure. Antiprotozoals: Metronidazole – Plasma concentrations are increased by Phenobarbital, with a consequent redu ...
Lexapro Name of Medicine
... While there is no specific data, the use of escitalopram in reduced renal function may be extrapolated from that of racemic citalopram. Escitalopram is expected to be eliminated more slowly in patients with mild to moderate reduction of renal function with no major impact on the escitalopram concent ...
... While there is no specific data, the use of escitalopram in reduced renal function may be extrapolated from that of racemic citalopram. Escitalopram is expected to be eliminated more slowly in patients with mild to moderate reduction of renal function with no major impact on the escitalopram concent ...
Full Prescribing Information for TOPAMAX® (topiramate)
... concomitant valproic acid use: Patients with inborn errors of metabolism or reduced mitochondrial activity may have an increased risk of hyperammonemia. Measure ammonia if encephalopathic symptoms occur (5.10) Kidney stones: Use with other carbonic anhydrase inhibitors, other drugs causing metabol ...
... concomitant valproic acid use: Patients with inborn errors of metabolism or reduced mitochondrial activity may have an increased risk of hyperammonemia. Measure ammonia if encephalopathic symptoms occur (5.10) Kidney stones: Use with other carbonic anhydrase inhibitors, other drugs causing metabol ...
abiraterone acetate - Therapeutic Goods Administration
... The major enzymes involved in the metabolism of abiraterone are CYP3A4 for phase I (oxidative) metabolites, the sulfotransferase (SULT) isozyme SULT2A1, and UDP-glucuronosyl transferase (UGT) UGT1A4. No studies have been conducted to determine if drugs that induce or inhibit these enzymes affect the ...
... The major enzymes involved in the metabolism of abiraterone are CYP3A4 for phase I (oxidative) metabolites, the sulfotransferase (SULT) isozyme SULT2A1, and UDP-glucuronosyl transferase (UGT) UGT1A4. No studies have been conducted to determine if drugs that induce or inhibit these enzymes affect the ...
Ofloxacin
Ofloxacin is a synthetic antibiotic of the fluoroquinolone drug class considered to be a second-generation fluoroquinolone.Ofloxacin was first patented in 1982 (European Patent Daiichi) and received approval from the U.S. Food and Drug Administration (FDA) on December 28, 1990. Ofloxacin is sold under a wide variety of brand names as well as generic drug equivalents, for oral and intravenous administration. Ofloxacin is also available for topical use, as eye drops and ear drops (marketed as Ocuflox and Floxin Otic respectively in the United States and marketed as Optiflox, eylox respectively in Jordan and Saudi Arabia).Ofloxacin is a racemic mixture, which consists of 50% levofloxacin (the biologically active component) and 50% of its “mirror image” or enantiomer dextrofloxacin.Ofloxacin has been associated with adverse drug reactions, such as tendon damage (including spontaneous tendon ruptures) and peripheral neuropathy (which may be irreversible); tendon damage may manifest long after therapy had been completed, and, in severe cases, may result in lifelong disabilities.